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Retinoids have been reported to inhibit the growth of several
breast cancer cell lines in culture (Lotan, 1979; Lacroix and
Lippman, 1980; Marth et al, 1985; Wetherall and Taylor, 1986;
Fontana et al, 1990) and to reduce breast tumour growth in animal
models (Rettura et al, 1975; Moon et al, 1976; Grubbs et al, 1977;
Moon et al, 1977). Furthermore, retinoic acid can augment the
action of other breast cancer cell growth inhibitors both in vitro
(Wetherall and Taylor, 1986; Fontana, 1987; Koga and Sutherland,
1991) and in vivo (Anzano et al, 1994). Following the success of
all-trans retinoic acid in differentiation therapy for acute pro-
myelocytic leukaemia (Kizaki et al, 1999; Slack 1999), interest
has increased in the potential use of retinoids for the prevention
(Costa, 1993) and treatment (Budd et al, 1998) of human breast
cancer. However, most of the reports of cell culture experiments
have exposed cells to retinoic acid for relatively short periods of
time (days). The key remaining question is whether retinoids
would still be effective against breast cancer cells if administered
long-term. There are reports of retinoic acid resistance in some
breast cancer cell sublines (Lacroix et al, 1984; Ueda et al, 1985;
Butler and Fontana, 1992) but no indication as to whether these
result from rare mutational events or as a general adaptive con-
sequence of long term exposure to retinoic acid.
Endocrine treatment is well known to be limited by the problem
of progression to resistance (Miller, 1996). Studies of oestro-
gen dependent human breast cancer cell lines in vitro show that
such cells have a remarkable ability to adapt to their environment
such that whatever the constraints imposed on growth, the cells
learn to escape growth inhibition and to regrow. This can occur
whether growth inhibition is imposed by oestrogen deprivation
(Katzenellenbogen et al, 1987; Welshons and Jordan, 1987; Daly
and Darbre, 1990; Jeng et al, 1998) or antioestrogen administra-
tion (Wakeling, 1993; Larssen et al, 1997). Much has been talked
of as oestrogen resistance but insofar as such cells retain oestrogen
receptor (ER) and oestrogen sensitive gene expression, the cells
only develop proliferative resistance to oestrogen.
Since overall growth of breast cancer cells results from a deli-
cate balance of cross-talk between different growth regulatory
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Summary Although retinoids are known to be inhibitory to breast cancer cell growth, a key remaining question is whether they would remain
effective if administered long-term. We describe here the long-term effects of all-trans retinoic acid on two oestrogen-dependent human
breast cancer cell lines MCF7 and ZR-75-1. Although both cell lines were growth inhibited by retinoic acid in the short-term in either the
absence or the presence of oestradiol, prolonged culture with 1 µ M all-trans retinoic acid resulted in the cells acquiring resistance to the
growth inhibitory effects of retinoic acid. Time courses showed that oestrogen deprivation of the cell lines resulted in upregulation of the basal
non-oestrogen stimulated growth rate such that cells learned to grow at the same rate without as with oestradiol, but the cells remained
growth inhibited by retinoic acid throughout. Addition of 1 µ M all-trans retinoic acid to steroid deprivation conditions resulted in reproducible
loss of growth response to both retinoic acid and oestradiol, although the time courses were separable in that loss of growth response to
retinoic acid preceded that of oestradiol. Loss of growth response to retinoic acid did not involve loss of receptors, ER as measured by steroid
binding assay or RARα as measured by Northern blotting. Function of the receptors was retained in terms of the ability of both oestradiol and
retinoic acid to upregulate pS2 gene expression, but there was reduced ability to upregulate transiently transfected ERE- and RRE-linked
reporter genes. Despite the accepted role of IGFBP3 in retinoic acid-mediated growth inhibition, progression to retinoic acid resistance
occurred irrespective of level of IGFBP3, which remained high in the resistant MCF7 cells. Measurement of AP1 activity showed that the two
cell lines had markedly different basal AP1 activities, but that progression to resistance was accompanied in both cases by a lost ability of
retinoic acid to reduce AP1 activity. These results warn of potential resistance which could arise on long-term treatment with retinoic acid in a
clinical situation and echo the problems of progression to endocrine resistance. It seems that whatever the constraints imposed on growth,
these cells have a remarkable ability to escape from growth inhibition. However, the ability of retinoic acid to delay progression to oestrogen
resistance is encouraging for endocrine therapy, and the concentration-dependence of retinoic acid resistance suggests that progression is
not absolute but could be manipulated by dose. © 2000 Cancer Research Campaign
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and various growth factors, resistance to one pathway has been
suggested to result from upregulation of alternative pathways.
There are several reports that retinoic acid action may be depen-
dent on other oestrogen and growth factor pathways. Retinoic acid
acts by binding to its nuclear receptors, the RARα , RARβ , RARγ ,
and as the 9-cis isomer through the retinoid X receptors, RXRα ,
RXRβ , RXRγ , to regulate gene expression at specific response
elements (RRE) (Chambon, 1996). Expression of RARα , RARβ
and RARγ have been found in many human breast cancer cell
lines, but RARα is higher in ER positive lines (Roman et al, 1992).
In these cells, oestrogen can regulate expression of RARα mRNA
(Roman et al, 1993), probably through the oestrogen response
element (ERE) upstream of the RARα gene (Rishi et al, 1995).
Experiments with selective retinoids (Dawson et al, 1995) and
with transfecting ER/RARα genes into ER negative cell lines
(Sheikh et al, 1993, 1994) suggest that RARα is central to the
mechanism of retinoic acid-induced growth inhibition in breast
cancer cells, although the importance of other retinoid receptors
cannot be ignored (Li et al, 1995). While oestrogen can regulate
RARα mRNA, conversely retinoic acid can downregulate ER
mRNA (Rubin et al, 1994) and can also inhibit downstream
oestrogen-induced gene expression (Fontana et al, 1992; Kazmi 
et al, 1996), suggesting a two-way interactive regulatory pathway.
On the growth factor side, retinoic acid has been found to inhibit
proliferation mediated through insulin-like growth factors (IGF)
(Fontana et al, 1991), by increasing the secretion of IGF binding
proteins (IGFBP) and in particular of IGFBP3 (Adamo et al, 1992;
Oh, 1998) through a mechanism dependent on both RARα and
RARβ (Shang et al, 1999).
This manuscript provides evidence that endocrine resistance is
not a unique phenomenon and that resistance to retinoic acid-
induced growth inhibition can also occur in vitro when cells are
exposed long term to this compound. Resistance occurs repro-
ducibly, without the loss of ER or RARα , and irrespective of the
level of IGFBP3.
MATERIALS AND METHODS
Cell lines
MCF7 McGrath human breast cancer cells were kindly provided
by Dr K Osborne at passage number 390 (Osborne et al, 1987) and
ZR-75-1 human breast cancer cells were kindly provided by
Professor M. Lippman (Engel et al, 1978). Both cell lines are
dependent on oestrogen for growth as described previously
(Darbre and Daly, 1989).
Culture of stock human breast cancer cell lines
Stock MCF7 cells were grown as monolayer cultures in
Dulbecco’s modified Eagle’s medium (DMEM) (Gibco BRL)
supplemented with 5% fetal calf serum (FCS) (Gibco BRL), 10 µ g/
ml insulin (Sigma, Poole, England) and 10–8 M oestradiol
(Steraloids, Croydon, England) in a humidified atmosphere of
10% carbon dioxide in air at 37° C. Oestradiol was dissolved in
ethanol and diluted 1/10 000 (v/v) in culture medium. ZR-75-1
cells were grown routinely as for MCF7 cells except for the omis-
sion of insulin from the medium. All cell stocks were subcultured
at weekly intervals by suspension with 0.06% trypsin-0.02%
EDTA (pH 7.3).
Culture of long-term oestrogen-deprived and retinoic
acid-treated cells
A new vial of cells was thawed from liquid nitrogen at the start of
each experiment which ensured that control cells of the starting
passage number were available for comparison at any time.
Freshly thawed cells were grown for 2 weeks as stock cultures
with oestrogen (see above) and then suspended with phenol-red-
free 0.06% trypsin-0.02% EDTA (pH 7.3), washed with phenol-
red-free RPMI 1640 medium (Gibco BRL) and replated in
phenol-red-free RPMI 1640 medium containing 5% dextran-
charcoal stripped FCS (DCFCS) (Darbre et al, 1983) with either
no further additions (for oestrogen-deprived conditions) or 10–6 M
all-trans-retinoic acid (retinoic acid treated cells). All-trans-
retinoic acid was dissolved at 10–2 M in dimethylsulphoxide and
diluted 1/10 000 (v/v) in culture medium. All experiments with
all-trans-retinoic acid were conducted under minimal light condi-
tions. For the study of whole cell populations, cells were subcul-
tured using phenol red-free 0.06% trypsin-0.02% EDTA (pH 7.3)
as necessary after 1 week, thereafter every 2–3 weeks during the
period of low growth and then increasing until eventually weekly.
For the study of clonal growth of cells, medium was changed
every 3–4 days but the cells were never subcultured. Well-
separated clones of cells were isolated by trypsinization using
cloning rings. Samples of whole cell cultures and individual clones
were frozen in liquid nitrogen at regular intervals for comparison.
Cell growth experiments
Cells were suspended from stock plates by treatment with phenol
red-free 0.06% trypsin-0.02% EDTA (pH 7.3), added to an equal
volume of phenol red-free RPMI 1640 medium containing 5%
DCFCS and counted on a haemocytometer. Cells were then added
to the required volume of phenol red-free RPMI 1640 medium
containing 5% DCFCS at a concentration of 0.2 × 105 cells/ml and
plated in monolayer in 0.5 ml aliquots into 24-well plastic tissue
culture dishes (Nunc). After 24 hours, the medium was changed to
phenol red-free RPMI 1640 medium supplemented with 5%
DCFCS and the appropriate concentration of oestradiol and all-
trans-retinoic acid. Culture medium was changed routinely every
3–4 days in all experiments. Cell counts were performed by
counting released nuclei on a model ZBI Coulter Counter, as
described previously (Daly and Darbre, 1990).
RNA extraction and Northern blotting
Cells for RNA extraction were suspended in phenol red-free RPMI
1640 medium containing 5% DCFCS at a concentration of 
0.2 × 105 cells/ml and plated in 16 ml aliquots into 9 cm plastic
tissue culture dishes (Nunc). After 24 hours, the medium was
changed to phenol red-free RPMI 1640 medium supplemented
with 5% DCFCS and the appropriate concentration of oestradiol
and all-trans-retinoic acid. After 7 days in culture, cells were
washed in situ with isotonic saline, harvested into ice-cold isotonic
saline using a rubber policeman and pelleted by centrifugation.
Whole cell RNA was prepared by the guanidinium-caesium chlo-
ride method (Sambrook et al, 1989) and analysed by Northern
blotting. Total cellular RNA was subjected to electrophoresis in
1.5% agarose-formaldehyde gels (Sambrook et al, 1989) at 20 µ g
RNA per track. RNA was transferred onto Hybond-N membranes
(Amersham International) and hybridized to 106 cpm of 32P
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Kpn1 fragment extending from the ATG to the BamH1 site in the
3′ non-coding region (kindly provided by R Evans) (Umesono 
et al, 1991). The pS2 cDNA probe was a 300-bp PstI fragment
(Masiakowski et al, 1982) and the 36B4 control DNA probe was
a 220-bp Pst1 fragment (Brown et al, 1984) (kindly provided by
P Chambon). DNA probes were 32P-radiolabelled by random
primer extension using a commercial kit (megaprime, Amersham
International). Hybridization was at 42° C for 18 h in 5× SSPE/5×
Denhardt’s solution/50% formamide/0.5% SDS/20 µ g/ml salmon
sperm DNA. Blots were washed at a stringency of 0.1× SSPE/0.1%
SDS at 65° C for 30 min and autoradiographed on Kodak XAR
film with intensifying screens at –70° C (Daly and Darbre, 1990).
Transient transfection assays
Three inducible constructs were used: RRE-LUC, ERE-CAT
(Daly et al, 1990) (kindly provided by M Parker) and AP1-CAT
(Soprano et al, 1996) (kindly provided by D Soprano). All
constructs consisted of the relevant response element sequence
inserted upstream of the thymidine kinase promoter and the
reporter gene. Reporter genes were either chloramphenicol acetyl
transferase (CAT) or firefly luciferase (LUC). Normalization of
data was achieved by cotransfection with a control constitutive
reporter construct. A constitutive CAT reporter gene was used 
to normalize RRE-LUC experiments, and a constitutive LUC
reporter gene was used to normalize ERE-CAT and AP1-CAT
experiments.
Cells were grown in monolayer culture in 3.5 cm tissue culture
dishes in phenol red-free DMEM with 5% DCFCS from a density
of 2.0 × 105 cells per dish for 7 days. Cells were then transfected
for 6 h with 5 µ g of inducible construct and 0.5 µ g of control
constitutive vector per dish using the calcium phosphate precipita-
tion method (Wigler et al, 1979). Cells were washed in phenol red-
free DMEM, shocked with 25% glycerol in DMEM for 1 min and
incubated overnight in phenol red-free RPMI1640 medium with
5% DCFCS. The following day, the medium was changed to 5%
DCFCS in phenol red-free RPMI1640 containing the required
concentration of oestradiol and/or all-trans-retinoic acid. Cells
were harvested 48 h later and assays for LUC activity performed
using a commercial kit (Promega) and assays for CAT activity
performed as described previously (Sleigh, 1986). All assays were
performed in duplicate on triplicate dishes of cells.
Western ligand blotting of IGFBP
Cells were plated onto 3.5-cm plastic tissue culture dishes in
phenol red-free RPMI 1640 medium with 5% DCFCS and left to
adhere overnight. After 24 hours the medium was changed to
include 10–8 M oestradiol and/or 10–6 M all-trans retinoic acid as
required. After 6 days, medium was changed to serum-free
medium: cells were washed twice with phenol red-free RPMI1640
medium and incubated in 1 ml of serum-free medium per dish
(phenol red-free RPMI 1640 medium with 15 mM HEPES buffer,
0.25% bovine serum albumin and any supplements of 10–8 M
oestradiol and 10–6 M all-trans retinoic acid as above) for a further
24 hours. Medium conditioned by the cells was collected, cellular
material removed by centrifugation, and medium stored at –70° C.
Cells remaining on each dish were counted on a Coulter counter as
above.
Aliquots of the conditioned medium were run on polyacry-
lamide gel electrophoresis, loading into each well the volume of
conditioned medium equivalent to 105 cells. Aliquots of condi-
tioned medium were each mixed with an equal volume of gel
sample buffer (26 mM Tris-HCl (pH 6.8), 2% sodium dodecyl
sulphate (SDS), 10% glycerol, 0.01% bromophenol blue), heated
to 100° C for 2 min and proteins separated by 15% polyacryl-
amide-SDS-gel electrophoresis. Proteins were transferred onto
Hybond C extra membrane by semi-dry blotting in 48 mM Tris/
39 mM glycine/1.3 mM SDS/20% methanol. Western blots were
hybridized to 125I-IGFI as described by Hossenlopp and coworkers
(1986). 125I-IGFI was prepared by the iodogen method (Salacinski
et al, 1981).
Measurement of oestrogen receptors (ER)
Freeze-fractured cell pellets from one 9-cm tissue culture dish
were homogenized in the ratio 1:8 parts buffer (10 mM Tris-HCl, 
1 mM EDTA, 2 mM DTT, 10% glycerol, 0.5 M NaCl, 4 mM
leupeptin, pH 7.4) at 4° C with ten passes through a teflon-glass
homogenizer. Homogenates were centrifuged at 105 000 g for 
1 hour at 4° C in a Sorvall ultracentrifuge and cytosols stored at
–70° C. Competitive binding assays using dextran-coated charcoal
(DCC) were performed on the cytosols as described elswhere
(Green and Leake, 1987). Incubations were performed for 18
hours at 4° C, and tubes were DCC-treated for 15 min at 4° C.
RESULTS
Short term effects of retinoic acid on growth of MCF7
cells
Oestrogen-maintained stock MCF7 cells grew slowly in the short-
term absence of oestradiol but showed a strong stimulation of
growth with addition of 10–8 M oestradiol. All-trans retinoic acid
at 10–6 M inhibited both the basal and oestrogen-stimulated growth
(Figure 1A). This growth experiment was repeated four times
during the course of the experiment with similar results.
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Figure 1 Effect of long-term retinoic acid treatment on the growth regulation
of MCF7 human breast cancer cells by oestradiol and all-trans retinoic acid in
monolayer culture. Cells were maintained either as stock cultures with 10–8 M
oestradiol (A), or under conditions of steroid deprivation (phenol red-free
RPMI 1640/5% DCFCS only) (B), or under conditions of steroid deprivation
with 10–6 M all-trans retinoic acid (C) for the length of time indicated. Short-
term growth was then assessed in phenol red-free RPMI 1640/5% DCFCS
medium alone (–E–RA) (open circles, dotted lines), or supplemented with
10–8 M oestradiol (+E) (solid circles, solid lines), with 10–6 M all-trans retinoic
acid (+RA) (open squares, solid lines), with 10–8 M oestradiol and 10–6 M all-
trans retinoic acid (+E+RA) (solid squares, solid lines). Bars indicate the
standard error of triplicate dishes, and where not seen, error was too small
for visual displayLong term effects of retinoic acid on growth of MCF7
cells
Experimental strategy
Long term effects of retinoic acid were studied by growing stock
cultures in oestrogen-depleted medium in the presence of 10–6 M
all-trans retinoic acid. However, since oestrogen deprivation 
alone has been shown to have consequences to cell growth
(Katzenellenbogen et al, 1987; Daly and Darbre, 1990), control
stock cultures were maintained in parallel in oestrogen-depleted
medium alone, in order to identify those effects specific to long
term retinoic acid treatment. Cells were assayed from both stock
cultures for cellular and molecular parameters at various time
intervals.
Cell biology
Long-term oestrogen deprivation of MCF7 cells resulted in a loss
of oestrogen sensitive growth, such that the basal growth in the
absence of oestradiol rose to the same rate as that in the presence
of 10–8 M oestradiol. Growth of these oestrogen-deprived cells
was, however, still strongly inhibited by the addition of 10–6 M all-
trans retinoic acid, either in the absence or in the presence of 
10–8 M oestradiol (Figure 1B). Long-term growth of the MCF7
cells for 36 weeks in the presence of 10–6 M all-trans retinoic acid
under steroid deprived conditions preserved some oestrogen sensi-
tivity of growth but showed a loss of growth inhibitory action by
retinoic acid, in that all-trans retinoic acid at 10–6 M now stimu-
lated growth of the cells either in the absence or in the presence of
10–8 M oestradiol (Figure 1C).
Time courses of the changes in the growth responses of the
long-term steroid deprived cells and of the long-term retinoic acid-
treated cells are shown in Figure 2. Steroid deprivation resulted in
an increased growth rate in the absence of oestradiol such that by
15 weeks the cells grew to a similar extent irrespective of the
absence or presence of 10–8 M oestradiol. Short-term growth
response to 10–6 M all-trans retinoic acid increased during the
course of the experiment but even after 98 weeks the steroid-
deprived cells remained growth inhibited by retinoic acid (Figure
2A). Long-term growth of MCF7 cells under conditions of steroid
deprivation has been carried out by two independent experiments
with similar results.
Long-term growth in the presence of 10–6 M all-trans retinoic
acid under steroid deprived conditions resulted in a loss of growth
response to retinoic acid by 36 weeks. The cells remained growth
stimulated by 10–8 M oestradiol but lost the inhibitory effect of
10–6 M all-trans retinoic acid at 36 weeks (Figure 1C, Figure 2B).
Longer term growth of these latter cells, however, resulted eventu-
ally also in loss of growth response to 10–8 M oestradiol as well 
as to 10–6 M all-trans retinoic acid (Figure 2B). Study of the
outgrowth of cells with long-term retinoic acid treatment showed,
in unsubcultured dishes, that the adaptation to growth in the
presence of retinoic acid was clonal but reproducibly gave several
clones (4–6) per 9-cm culture dish. Studies of long-term retinoic
acid treated cells were carried out on both subcultured stock dishes
and on stock dishes never subcultured with clonal outgrowths indi-
vidually isolated. Results in this paper are given for the clonal
outgrowth of cells termed RR6, but similar time courses were
obtained for subcultured dishes termed RRsub and a second clonal
outgrowth of cells termed RR8 (data not shown here but described
in a PhD thesis (Stephen, 1998)).
Loss of growth inhibition by 10–6 M all-trans retinoic acid in the
long-term retinoic acid treated cells was accompanied by loss of
inhibitory growth effects also of the 9-cis isomer. Long-term (103
weeks) retinoic acid treated cells were plated in a growth experi-
ment at a density of 0.15 × 105 cells per dish and grew over 14
days to a density without retinoic acid of 2.001   0.001 × 105 cells
per dish, with 10–6 M all-trans retinoic acid of 2.003   0.077 × 105
cells per dish, and with 10–6 M 9-cis retinoic acid of 2.027   0.046
× 105 cells per dish.
A separate experiment, however, suggested that loss of growth
inhibition was a concentration-dependent phenomenon in that
some growth inhibitory effects could still be detected by raising
levels to 10–5 M all-trans retinoic acid. Long-term (56 weeks)
retinoic acid treated cells were plated in a growth experiment at
a density of 0.26 × 105 cells per dish and ended after 14 days at a
density without retinoic acid of 1.885   0.0044 × 105 cells per
dish, with 10–8 M all-trans retinoic acid of 1.928 ± 0.155 × 105
cells per dish, with 10–7 M all-trans retinoic acid of 1.958   0.030
× 105 cells per dish, with 10–6 M all-trans retinoic acid of 1.981  
0.036 × 105 cells per dish, but with 10–5 M all-trans retinoic acid of
1.369    0.070  × 105 cells per dish and with 10–4 M all-trans
retinoic acid of 0.081   0.003 × 105 cells per dish.
Expression of ER and RARα
Loss of growth response to oestradiol did not correlate with any
loss of oestrogen receptor. Measurement of total salt-extractable
ER in the stock oestrogen-maintained MCF7 cells gave a value of
7.5   1.5 fmol/mg protein, as measured by competitive binding
assay. Comparative assays showed increased levels of ER in
MCF7 cells deprived of oestrogen for 110 weeks (78.4   4.6
fmol/mg protein) and in MCF7 cells treated with retinoic acid for
99 weeks (44.4   1.1 fmol/mg protein).
Since RARα has been implicated as the major mediator of
proliferative effects of retinoic acid in ER positive breast cancer
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Figure 2 Time course of the changes in growth response to oestradiol and
all-trans retinoic acid of MCF7 human breast cancer cells in monolayer
culture following long term retinoic acid treatment. Cells were grown for
increasing periods of time under conditions of steroid deprivation (phenol red-
free RPMI 1640/5% DCFCS only) (A), or under conditions of steroid
deprivation with 10–6 M all-trans retinoic acid (B). Short-term growth was then
assessed over 14 days in phenol red-free RPMI 1640/5% DCFCS medium
alone (–E–RA) (open circles, dotted lines), or supplemented with 10–8 M
oestradiol (+E) (solid circles, solid lines) or with 10–6 M all-trans retinoic acid
(+RA) (open squares, solid lines). Bars indicate the standard error of
triplicate dishes, and where not seen, error was too small for visual displaycells (see introduction), we measured RARα mRNA levels by
Northern blotting. Two mRNA species were found for RARα
mRNA as documented by others (Roman et al, 1992). Levels of
RARα mRNA did not vary to any large extent following short-
term (7 day) removal of oestrogen or retinoic acid treatment of
stock oestrogen-maintained MCF7 cells (Figure 3, tracks 1–4).
However, longer term removal of oestrogen did result in loss of
RARα mRNA (Figure 3, track 5) which could be reinduced with
either 10–8 M oestradiol or 10–6 M all-trans retinoic acid (Figure 3,
tracks 6–8). Long-term retinoic acid treatment resulted in retention
of RARα mRNA at levels similar to those in the oestrogen-
maintained cells and which again were not altered to any major
extent by short term (7 day) removal of retinoic acid or oestrogen
administration (Figure 3, tracks 9–12).
Function of oestrogen and retinoic acid receptors
Although changes in growth responses were not accompanied by
loss of ER or RARα , it is possible that downstream events in
receptor function were altered. Transient transfection of an RRE-
LUC gene into the oestrogen-maintained MCF7 cells confirmed
that all-trans retinoic acid could induce luciferase activity in those
cells, but following long-term retinoic acid treatment the induction
of the same transfected gene was considerably reduced (Figure 4A).
A similar result was obtained for induction of a transiently trans-
fected oestrogen-inducible ERE-CAT gene (Figure 4B), in that the
oestrogen induction of CAT activity was considerably reduced in
long-term steroid deprived or retinoic acid treated cells compared
with the oestrogen-maintained cells.
Other studies of oestrogen receptor function, by contrast,
showed that oestrogen regulation of pS2 gene expression was not
impaired in the long term steroid deprived and retinoic acid treated
cells (Figure 3). Short-term removal of oestrogen (1 week) from
oestrogen-maintained cells resulted in reduced pS2 mRNA levels
which could be reinduced by oestradiol but not by retinoic acid
(Figure 3, tracks 1–4). Longer term removal of oestrogen (68
weeks) resulted in undetectable levels of pS2 mRNA which could
be reinduced by oestradiol and weakly also by retinoic acid
(Figure 3, tracks 5–8). Long-term retinoic acid treatment preserved
pS2 mRNA expression (Figure 3, cf tracks 5 and 9) although
oestradiol could still increase levels further (Figure 3, tracks
9–12).
Long term effects of retinoic acid on growth of ZR-75-1
cells
In order to determine general applicability of results from MCF7
cells, experiments were carried out in a second oestrogen-
regulated human breast cancer cell line ZR-75-1. Stock oestrogen-
maintained ZR-75-1 cells grew slowly in the short-term absence of
oestrogen, and growth was stimulated by 10–8 M oestradiol and
inhibited by 10–6 M all-trans retinoic acid (Figure 5A). Effects of
long-term oestrogen deprivation in these cells have been described
previously (Daly and Darbre, 1990). Long-term retinoic acid treat-
ment of these cells under conditions of steroid deprivation resulted
in loss of growth response to either oestradiol or all-trans retinoic
acid (Figure 5B). Basal growth of the cells in the absence of
oestrogen rose to the same rate as that in the presence of oestradiol
and growth was no longer inhibited by 10–6 M all-trans retinoic
acid. Previous work (Daly and Darbre, 1990) has shown that long
term oestrogen deprivation does not result in loss of ER number or
in loss of ER function as measured by oestrogen regulation of pS2
mRNA gene expression on Northern blotting. Long-term retinoic
Retinoic acid resistance in breast cancer cells 1187
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Figure 3 Regulation of RARα mRNA in MCF7 human breast cancer cells
following long-term retinoic acid treatment. Northern blots of whole cell RNA
(20 µ g per track) from stock oestrogen-maintained cells (tracks 1–4), or from
cells following 68 weeks of steroid deprivation (phenol red-free RPMI
1640/5% DCFCS medium) (tracks 5–8), or from cells following 112 weeks of
steroid deprivation in the presence of 10–6 M all-trans retinoic acid (tracks
9–12). Short-term regulation of gene expression was assessed in each stock
line following growth for 7 days in RPMI 1640/5% DCFCS medium alone (–)
(tracks 1, 5, 9), or supplemented with 10–8 M oestradiol (E) (tracks 2, 6, 10),
with 10–6 M all-trans retinoic acid (RA) (tracks 3, 7, 11), or with 10–8 M
oestradiol and 10–6 M all-trans retinoic acid (E+RA) (tracks 4, 8, 12). Blots
were probed for RARα mRNA and oestrogen-regulated pS2 mRNA. Equal
loading of RNA samples was controlled by probing for the constitutively
expressed 36B4 mRNA
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Figure 4 Effect of long-term retinoic acid treatment on function of retinoic
acid receptors (A) and oestrogen receptors (B) in MCF7 human breast
cancer cells. Function of receptors was assayed by transient transfection of
an RRE-LUC gene or of an ERE-CAT gene respectively. Cells were
maintained either as stock cultures with 10–8 M oestradiol (cell line +E), or
under conditions of steroid deprivation (phenol red-free RPMI 1640/5%
DCFCS only) (cell line –E–RA), or under conditions of steroid deprivation
with 10–6 M all-trans retinoic acid (cell line –E+RA) for the length of time
indicated. Short-term expression of the transfected gene was then assessed
as described in ‘Materials and Methods’ in phenol red-free RPMI 1640/5%
DCFCS medium alone (–) (open bars), or supplemented with 10–8 M
oestradiol (E) (solid bars), with 10–6 M all-trans retinoic acid (RA) (wide lines),
with 10–8 M oestradiol and 10–6 M all-trans retinoic acid (E+RA) (close lines).
Luciferase activity was expressed as optical density units of maximal light
emission normalized per unit of CAT activity. CAT activity was expressed as
pmols of 14C-acetyl group transferred from 14C-acetyl CoA to chloramphenicol
per hour and normalized per unit of luciferase activity. All results are
expressed as a fold induction ratio of treatment versus no treatment. Bars
indicate the standard error of triplicate dishes of both no treatment and
treatmentacid treatment did result here in reduced ability for oestrogen to
induce CAT activity from a transiently transfected ERE-CAT gene
(Figure 6), as in the MCF7 cells (Figure 4).
Expression of IGFBP3 after long-term RA exposure
Since retinoic acid inhibition of cell growth is thought to be asso-
ciated with increased levels of growth inhibitory IGFBP3 (see
introduction), levels of IGFBP3 were measured by Western ligand
blotting in the long-term steroid deprived and retinoic acid treated
cells. Stock oestrogen-maintained cells produced low levels of
several IGFBP. The largest band, IGFBP3, was strongly increased
by 10–6 M all-trans retinoic acid not only in both the MCF7 and
ZR-75-1 oestrogen-maintained stock cells but also in the long-
term oestrogen deprived MCF7 cells (Figure 7, tracks 1–8, 13–16).
Long-term retinoic acid treated ZR-75-1 cells had only low levels
of IGFBP3 equivalent to those seen without retinoic acid in the
stock cells, whereas long-term retinoic acid treated MCF7 cells
showed higher levels of IGFBP3 which were not reduced by short-
term removal of retinoic acid or oestradiol administration (Figure 7,
tracks 9–12, 17–20).
AP1 activity after long-term RA exposure
Level of AP1 activity is thought to play a role in retinoic acid
sensitivity in breast cancer cells (van der Burg et al, 1995).
Transient transfection of an AP1-CAT inducible reporter gene into
stock oestrogen-maintained MCF7 and ZR-75-1 cells showed that
AP1 activity was decreased in both cases by the administration of
10–6 M all-trans retinoic acid (Table 1), although it was evident
that the basal level of AP1 activity was much greater in the
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Figure 5 Effect of long-term retinoic acid treatment on the growth
regulation of ZR-75-1 human breast cancer cells by oestradiol and all-trans
retinoic acid in monolayer culture. Cells were maintained either as stock
cultures with 10–8 M oestradiol (A), or under conditions of steroid deprivation
(phenol red-free RPMI 1640/5% DCFCS) with 10–6 M all-trans retinoic acid
(B) for the length of time indicated. Short-term growth was then assessed in
phenol red-free RPMI 1640/5% DCFCS medium alone (–E–RA) (open
circles, dotted lines), or supplemented with 10–8 M oestradiol (+E) (solid
circles, solid lines) or with 10–6 M all-trans retinoic acid (+RA) (open squares,
solid lines). Bars indicate the standard error of triplicate dishes, and where
not seen, error was too small for visual display
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Figure 6 Effect of long-term retinoic acid treatment on function of oestrogen
receptors in ZR-75-1 human breast cancer cells. Function of receptors was
assayed by transient transfection of an ERE-CAT gene. Cells were
maintained either as stock cultures with 10–8 M oestradiol (cell line +E), or
under conditions of steroid deprivation (phenol red-free RPMI 1640/5%
DCFCS) with 10–6 M all-trans retinoic acid (cell line –E+RA) for the length of
time indicated. Short-term expression of the transfected gene was then
assessed as described in ‘Materials and Methods’ in phenol red-free RPMI
1640/5% DCFCS medium alone (–) (open bars), or supplemented with 
10–8 M oestradiol (E) (solid bars), with 10–6 M all-trans retinoic acid (RA)
(wide lines), with 10–8 M oestradiol and 10–6 M all-trans retinoic acid (E+RA)
(close lines). CAT activity was expressed as pmol of 14C-acetyl group
transferred from 14C-acetyl CoA to chloramphenicol per hour and normalized
per unit of luciferase activity. All results are expressed as a fold induction
ratio of treatment versus no treatment. Bars indicate the standard error of
triplicate dishes of both no treatment and treatment
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Figure 7 Regulation of IGFBP in MCF7 and ZR-75-1 human breast cancer
cells following long-term retinoic acid treatment. Western 125I-IGF1 ligand blot
analysis of oestrogen-maintained cells (tracks 1–4 and 13–16), or of cells
following steroid deprivation (phenol red-free RPMI 1640/5% DCFCS
medium) (tracks 5–8), or of cells following steroid deprivation in the presence
of 10–6 M all-trans retinoic acid (tracks 9–12 and 17–20). Short-term
regulation of IGFBP was assessed in each stock line following growth for 7
days in RPMI 1640/5% DCFCS medium alone (–) (tracks 1, 5, 9, 13, 17), or
supplemented with 10–8 M oestradiol (E) (tracks 2, 6, 10, 14, 18), with 10–6 M
all-trans retinoic acid (RA) (tracks 3, 7, 11, 15, 19), or with 10–8 M oestradiol
and 10–6 M all-trans retinoic acid (E+RA) (tracks 4, 8, 12, 16, 20). The
positions of 14C-labelled protein molecular weight markers (MW) are shown in
the left hand lanes
Table 1 Effect of 10–6 M all-trans retinoic acid (RA) on induction of CAT
activity from a transiently transfected AP1-CAT gene in MCF7 and ZR-75-1
human breast cancer cells in monolayer culture
Long-term With or without RA CAT activity
treatment of cells in CAT assay (pmol 14C-acetyl/unit luciferase/h)
MCF7 –RA 6.8   0.6
(E-maintained) +RA 3.6   0.6
MCF7 –RA 18.7   0.8
(+RA 66 wks) +RA 29.8   4.0
ZR-75-1 –RA 101.5   3.3
(E-maintained) +RA 63.9   5.8
ZR-75-1 –RA 266.8   15.7
(+RA 48 wks) +RA 322.4   12.2ZR-75-1 cells. Long-term retinoic acid treatment resulted in an
altered AP1 response to retinoic acid in both cell lines, such that
retinoic acid became stimulatory rather than inhibitory (Table 1).
DISCUSSION
This paper has described the long-term effects of all-trans retinoic
acid on two oestrogen-dependent human breast cancer cell lines
MCF7 and ZR-75-1. Although both cell lines were inhibited by
retinoic acid in the short term in either the absence or the presence
of oestradiol, prolonged culture with retinoic acid resulted in
the cells acquiring resistance to the growth inhibitory effects
of retinoic acid. Long term culture in the presence of 1 µ M all-
trans retinoic acid resulted in reproducible upregulation of growth
as time increased, until the cells were no longer growth inhibited
by retinoic acid in either the absence or in the presence of oestra-
diol. Loss of response to retinoic acid was also accompanied by a
loss of response to the growth stimulatory effects of oestradiol,
although the time courses were separable. The time courses of loss
of growth response to oestrogen under conditions of steroid depri-
vation have been documented previously for T47D and ZR-75-1
cells (Daly and Darbre, 1990). Steroid deprivation of MCF7 cells
showed here a similar pattern of upregulation of basal non-
oestrogen stimulated growth rate such that the cells learned to
grow at the same rate in the absence of oestrogen as they grew with
oestradiol throughout. However, loss of oestrogen growth
response took less time in the MCF7 cells (15 weeks) than with
T47D cells (32 weeks) (Daly and Darbre, 1990) or with ZR-75-1
cells (35–40 weeks) (Daly and Darbre, 1990). Addition of retinoic
acid to the steroid deprived conditions preserved the oestrogen
growth response of the MCF7 cells from 15 weeks to greater than
36 weeks (36–55 weeks), and was therefore separable from the
loss of growth inhibitory effects of all-trans retinoic acid which
had occurred already at 36 weeks.
Study of the outgrowth of cells under conditions of steroid
deprivation and retinoic acid treatment in unsubcultured dishes
revealed that the progression to resistance was clonal but it was
reproducible in that many clones were visible on every dish with
increasing time, and both individual clones and mixed unsubcul-
tured cell populations followed similar time courses. This rein-
forces previous suggestions (Daly and Darbre, 1990) that loss of
response results from adaptive growth changes which occur within
a specific time frame for each cell line. Unfortunately the time
frame was not the same for different cell lines, presumably due to
the prevailing cellular context and in line with clinical observa-
tions of different lengths of remission to endocrine treatment in
different patients (Miller, 1996).
The generation of cell populations all derived from the same
parental cell line at various time points on the pathway to
oestrogen resistance and retinoic acid resistance provides a cell
biological model system to investigate molecular mechanisms.
Loss of response to either oestrogen or retinoic acid did not result
from loss of oestrogen receptors as measured by steroid binding
assay. In fact, ER levels were increased in MCF7 cells 10-fold
following long-term steroid deprivation and 6-fold in the steroid
deprived retinoic acid-treated cells. This is in line with the ability
of both oestrogen (Saceda et al, 1988) and retinoic acid (Rubin
et al, 1994) to downregulate ER levels. Nor was loss of response to
retinoic acid associated with loss of RARα mRNA as measured by
Northern blotting, despite the fact that this receptor is thought to be
a key mediator of retinoic acid growth inhibitory effects in MCF7
cells (Dawson et al, 1995). Regulation of RARα mRNA was not
obvious in the short term by either oestrogen or retinoic acid in the
oestrogen-maintained cells, but when in the long-term oestrogen
deprived cells the levels fell to undetectable, there was an obvious
increase not only by short-term readddiction of oestrogen as
reported previously (Roman et al, 1993) but also by retinoic acid
itself. Although the short-term regulation of RARα mRNA in the
steroid deprived cells was not as strong with retinoic acid as with
oestrogen, long-term treatment with retinoic acid could clearly
compensate for lack of oestrogen in maintaining RARα mRNA
levels and these could not be obviously altered by short-term
manipulations. Thus, although retinoic acid resistance in ER nega-
tive breast cancer cell lines has been linked to underexpression of
RARα mRNA (van der Burg, 1993), progression to retinoic acid
resistance could occur here by adaptation within the same cell line
without loss of RARα mRNA. Other studies (data not shown here
but published in a PhD thesis (Stephen, 1998)) showed also by
Northern blotting that neither RARγ nor RXRα mRNA levels
decreased in the long-term retinoic acid treated cells compared
with the stock oestrogen-maintained MCF7 cells. Published work
has shown that overexpression of RARβ can restore retinoic acid
sensitivity to the ER negative breast cancer cell line MDA-MB-
231 (Li et al, 1995) and it would be interesting to explore any role
for this receptor in the context of the ER positive MCF7 cells
which have developed retinoic acid resistance.
Despite the continued presence of receptors ER/RARα , their
function was reduced in some assays. As reported previously for
steroid deprived ZR-75-1 cells (Daly and Darbre, 1990), Northern
blotting of oestrogen-regulated pS2 mRNA showed no loss of
function of ER in either steroid deprived or retinoic acid acid
treated MCF7 cells. Furthermore, pS2 was increased not only by
oestradiol but also by retinoic acid in the long-term steroid
deprived cells. Inhibitory effects of retinoic acid on oestrogen
action at the ERE level have been reported previously
(Demirpence et al, 1994), but here we have noted positive effects
of retinoic acid on an oestrogen-regulated gene in the absence of
oestrogen. In contrast to endogenous pS2 gene expression, levels
of induction of transiently transfected ERE-CAT and RRE-LUC
reporter genes were reduced in the steroid deprived and retinoic
acid treated cells but the reasons remain unknown.
Our results confirm previous work showing that retinoic acid
treatment increases secretion of IGFBP3 into the medium condi-
tioned by stock oestrogen maintained retinoic-inhibited MCF7 or
ZR-75-1 cells. This was also true for the steroid deprived MCF7
cells and occurred in both the absence and the presence of oestra-
diol. However, the progression to retinoic acid growth resistance
occurred in the long-term retinoic acid treated cells irrespective of
continued high levels of IGFBP3 secreted from the MCF7 cells or
reduced levels of IGFBP3 from the ZR-75-1 cells. If IGFBP3 is a
mediator of retinoic acid-induced growth inhibition in breast
cancer cells as some studies strongly indicate (Adamo et al, 1992;
Oh, 1998; Shang et al, 1999), then our data would suggest that
progression to resistance must be able to occur through some
independent overriding pathway.
Transcriptional activity of AP1-linked genes has been another
suggested site for interaction of retinoic acid and growth factor
regulatory pathways (Gottlicher et al, 1998). Activity of the
transcription factor AP1 is induced by mitogenic growth factors
(Lamph et al, 1988) while growth inhibitors such as retinoids
decrease its activity (Chen et al, 1995) through specific protein–
protein interactions (DiSepio et al, 1999). In ER positive retinoic
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activity while in ER negative retinoic acid resistant breast cancer
cells retinoic acid could not alter AP1 activity (van der Burg et al,
1995). Furthermore, the antiproliferative effects of retinoic acid
can be overcome in MCF7 cells by overexpression of c-jun (Yang
et al, 1997). Our results here confirm that AP1 activity is reduced
by retinoic acid in oestrogen-maintained retinoic acid sensitive
breast cancer cells, but not in their long-term retinoic acid main-
tained and resistant counterparts. Comparison of MCF7 and ZR-
75-1 cell lines showed that different ER positive cell lines have
markedly different basal AP1 activities and thus that level of AP1
activity did not equate with growth resistance to retinoic acid.
However, comparison of the retinoic acid sensitive with resistant
counterparts of the same parental origin does suggest a correlation
between loss of growth response to retinoic acid and loss of 
the ability of retinoic acid to reduce endogenous AP1 activity.
Progression to retinoic acid resistance may thus be accompanied
by a lost ability of retinoic acid to reduce AP1 levels rather than
relate to any absolute value for AP1 levels. The mechanisms
remain unknown, but could relate to altered metabolism rendering
the retinoic acid ineffective (Takatsuka et al, 1996), and are in line
with other recent data linking the multidrug resistant (MDR)
phenotype with increased AP1 activity (Daschner et al, 1999).
If there is any validity in extrapolation from cell culture to
human tumours, then these results warn of potential resistance
which could arise on long term treatment with retinoic acid in 
the clinical situation, and echo the problems of progression to
endocrine resistance (Miller, 1996). However, since resistance
to retinoic acid was separable from resistance to oestrogen, and
since retinoic acid could delay progression to oestrogen resistance,
this may offer the opportunity for development of alternating alter-
native therapies. Furthermore, since progression to retinoic acid
resistance was concentration-dependent, progression can no
longer be considered as absolute but rather as a mechanism of
escape from prevailing environmental conditions. Oestrogen resis-
tance has recently been shown also to follow a similar course to
altered rather than lost sensitivity (Jeng et al, 1998). This may
offer further clinical possibilities for manipulation of dose as well
as type of therapy.
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